 Carlos Roncal
Concepts (220)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uric Acid | 14 | 2019 | 166 | 1.020 |
Why?
| | Fructose | 13 | 2018 | 132 | 0.930 |
Why?
| | Kidney Diseases | 9 | 2019 | 427 | 0.730 |
Why?
| | Hyperuricemia | 8 | 2019 | 47 | 0.590 |
Why?
| | Metabolic Syndrome | 7 | 2018 | 356 | 0.520 |
Why?
| | Allopurinol | 4 | 2019 | 70 | 0.430 |
Why?
| | Diabetic Nephropathies | 6 | 2019 | 319 | 0.360 |
Why?
| | Kidney | 11 | 2019 | 1499 | 0.340 |
Why?
| | Nephritis, Interstitial | 2 | 2007 | 11 | 0.320 |
Why?
| | Captopril | 1 | 2009 | 11 | 0.310 |
Why?
| | Antimetabolites | 1 | 2009 | 21 | 0.300 |
Why?
| | Uromodulin | 2 | 2019 | 22 | 0.290 |
Why?
| | Rats, Sprague-Dawley | 15 | 2019 | 2541 | 0.280 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2009 | 226 | 0.270 |
Why?
| | Arteriolosclerosis | 1 | 2007 | 1 | 0.270 |
Why?
| | Rats | 18 | 2019 | 5616 | 0.270 |
Why?
| | Lead | 1 | 2007 | 70 | 0.250 |
Why?
| | Cisplatin | 1 | 2007 | 336 | 0.220 |
Why?
| | Diabetes Mellitus, Type 1 | 5 | 2019 | 3906 | 0.210 |
Why?
| | Vascular Stiffness | 2 | 2019 | 487 | 0.210 |
Why?
| | Hypokalemia | 3 | 2008 | 24 | 0.200 |
Why?
| | Glucose | 5 | 2018 | 1049 | 0.190 |
Why?
| | Glomerular Filtration Rate | 5 | 2019 | 764 | 0.190 |
Why?
| | Albuminuria | 3 | 2019 | 190 | 0.190 |
Why?
| | Endothelium, Vascular | 4 | 2019 | 965 | 0.180 |
Why?
| | Acute Kidney Injury | 2 | 2007 | 870 | 0.180 |
Why?
| | Dietary Sucrose | 3 | 2010 | 49 | 0.170 |
Why?
| | Chemokine CCL2 | 4 | 2009 | 117 | 0.160 |
Why?
| | Creatinine | 6 | 2018 | 510 | 0.150 |
Why?
| | Kidney Tubules | 4 | 2008 | 117 | 0.150 |
Why?
| | Glycocalyx | 1 | 2019 | 30 | 0.150 |
Why?
| | Glycopeptides | 1 | 2019 | 44 | 0.150 |
Why?
| | Dehydration | 2 | 2016 | 56 | 0.140 |
Why?
| | Sweetening Agents | 2 | 2009 | 57 | 0.140 |
Why?
| | Kidney Calculi | 1 | 2018 | 45 | 0.140 |
Why?
| | Animals | 26 | 2019 | 38180 | 0.140 |
Why?
| | Dietary Carbohydrates | 2 | 2009 | 151 | 0.130 |
Why?
| | Heat-Shock Response | 1 | 2018 | 78 | 0.130 |
Why?
| | Hydrochlorothiazide | 2 | 2007 | 7 | 0.130 |
Why?
| | Sodium Bicarbonate | 1 | 2018 | 47 | 0.130 |
Why?
| | Sugars | 1 | 2018 | 41 | 0.130 |
Why?
| | Diuretics | 2 | 2007 | 68 | 0.130 |
Why?
| | Hypertension, Renal | 2 | 2007 | 15 | 0.130 |
Why?
| | Proteinuria | 5 | 2008 | 103 | 0.130 |
Why?
| | Oxidative Stress | 4 | 2019 | 1341 | 0.120 |
Why?
| | Survival | 1 | 2016 | 38 | 0.120 |
Why?
| | Water Supply | 1 | 2016 | 89 | 0.110 |
Why?
| | Antineoplastic Agents | 1 | 2007 | 2202 | 0.110 |
Why?
| | Metabolic Diseases | 1 | 2016 | 114 | 0.110 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2018 | 266 | 0.110 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2008 | 557 | 0.110 |
Why?
| | Farmers | 1 | 2015 | 69 | 0.110 |
Why?
| | Heat Stress Disorders | 1 | 2015 | 84 | 0.100 |
Why?
| | Male | 23 | 2019 | 72629 | 0.100 |
Why?
| | Dietary Supplements | 1 | 2018 | 576 | 0.100 |
Why?
| | Climate Change | 1 | 2016 | 200 | 0.100 |
Why?
| | Immunohistochemistry | 5 | 2008 | 1718 | 0.090 |
Why?
| | Macrophages | 4 | 2010 | 1514 | 0.090 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 4 | 2008 | 983 | 0.090 |
Why?
| | Blood Pressure | 6 | 2009 | 1771 | 0.090 |
Why?
| | Body Weight | 4 | 2009 | 980 | 0.090 |
Why?
| | Kidney Tubules, Proximal | 2 | 2010 | 130 | 0.090 |
Why?
| | Inflammation | 3 | 2008 | 2881 | 0.090 |
Why?
| | Liver | 2 | 2018 | 1893 | 0.090 |
Why?
| | Drug Synergism | 2 | 2009 | 357 | 0.090 |
Why?
| | Intercellular Adhesion Molecule-1 | 2 | 2009 | 138 | 0.080 |
Why?
| | Hypertension | 4 | 2008 | 1266 | 0.080 |
Why?
| | Urate Oxidase | 2 | 2008 | 13 | 0.080 |
Why?
| | Insulin Resistance | 5 | 2009 | 1243 | 0.080 |
Why?
| | Capillaries | 2 | 2007 | 125 | 0.070 |
Why?
| | Disease Models, Animal | 6 | 2009 | 4580 | 0.070 |
Why?
| | Animal Feed | 1 | 2009 | 54 | 0.070 |
Why?
| | Xanthine Oxidase | 1 | 2009 | 79 | 0.070 |
Why?
| | Angiostatins | 1 | 2008 | 3 | 0.070 |
Why?
| | Cells, Cultured | 6 | 2019 | 4156 | 0.070 |
Why?
| | Weight Gain | 2 | 2008 | 564 | 0.070 |
Why?
| | Kidney Glomerulus | 1 | 2008 | 128 | 0.070 |
Why?
| | Chronic Disease | 3 | 2008 | 1814 | 0.060 |
Why?
| | Biomarkers | 4 | 2019 | 4284 | 0.060 |
Why?
| | Leptin | 1 | 2008 | 247 | 0.060 |
Why?
| | Fatty Liver | 1 | 2009 | 251 | 0.060 |
Why?
| | Drug Therapy, Combination | 1 | 2009 | 1048 | 0.060 |
Why?
| | Dietary Fats | 1 | 2008 | 315 | 0.060 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2007 | 2032 | 0.060 |
Why?
| | Inflammation Mediators | 2 | 2008 | 509 | 0.060 |
Why?
| | Neovascularization, Pathologic | 1 | 2008 | 286 | 0.060 |
Why?
| | Renal Circulation | 1 | 2006 | 75 | 0.060 |
Why?
| | Renal Insufficiency | 1 | 2008 | 173 | 0.060 |
Why?
| | Nitric Oxide | 5 | 2008 | 897 | 0.060 |
Why?
| | Enzyme Inhibitors | 1 | 2009 | 826 | 0.060 |
Why?
| | Hydrogen-Ion Concentration | 2 | 2018 | 563 | 0.060 |
Why?
| | Gout Suppressants | 2 | 2019 | 20 | 0.050 |
Why?
| | Chemokines | 1 | 2005 | 218 | 0.050 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2007 | 851 | 0.050 |
Why?
| | Th1 Cells | 1 | 2005 | 139 | 0.050 |
Why?
| | Fructokinases | 2 | 2018 | 41 | 0.050 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2009 | 2592 | 0.050 |
Why?
| | Young Adult | 5 | 2019 | 14163 | 0.050 |
Why?
| | Interleukin-10 | 1 | 2005 | 310 | 0.050 |
Why?
| | Organ Size | 3 | 2010 | 463 | 0.050 |
Why?
| | Risk Factors | 4 | 2019 | 10816 | 0.050 |
Why?
| | Energy Metabolism | 1 | 2009 | 946 | 0.050 |
Why?
| | Kidney Failure, Chronic | 2 | 2005 | 598 | 0.050 |
Why?
| | Rats, Wistar | 2 | 2018 | 451 | 0.050 |
Why?
| | Cell Proliferation | 1 | 2010 | 2506 | 0.050 |
Why?
| | RNA, Messenger | 2 | 2007 | 2833 | 0.040 |
Why?
| | Humans | 18 | 2019 | 145307 | 0.040 |
Why?
| | Endothelial Cells | 1 | 2008 | 872 | 0.040 |
Why?
| | Aorta | 2 | 2019 | 431 | 0.040 |
Why?
| | Adolescent | 5 | 2019 | 22507 | 0.040 |
Why?
| | Blotting, Western | 3 | 2008 | 1187 | 0.040 |
Why?
| | Case-Control Studies | 2 | 2019 | 3613 | 0.040 |
Why?
| | Fibrosis | 3 | 2008 | 550 | 0.040 |
Why?
| | Blood Urea Nitrogen | 2 | 2009 | 53 | 0.040 |
Why?
| | Calcium Oxalate | 1 | 2018 | 7 | 0.040 |
Why?
| | Half-Life | 1 | 2018 | 153 | 0.040 |
Why?
| | Biological Availability | 1 | 2018 | 142 | 0.030 |
Why?
| | Microscopy, Polarization | 1 | 2018 | 31 | 0.030 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 1 | 2018 | 41 | 0.030 |
Why?
| | High Fructose Corn Syrup | 1 | 2018 | 8 | 0.030 |
Why?
| | Carbonated Beverages | 1 | 2018 | 16 | 0.030 |
Why?
| | Pulse Wave Analysis | 1 | 2019 | 266 | 0.030 |
Why?
| | Osmolar Concentration | 1 | 2018 | 167 | 0.030 |
Why?
| | Area Under Curve | 1 | 2018 | 332 | 0.030 |
Why?
| | Lipogenesis | 1 | 2018 | 62 | 0.030 |
Why?
| | Beverages | 1 | 2018 | 69 | 0.030 |
Why?
| | Potassium | 2 | 2008 | 152 | 0.030 |
Why?
| | Diabetic Angiopathies | 1 | 2019 | 263 | 0.030 |
Why?
| | ROC Curve | 1 | 2018 | 615 | 0.030 |
Why?
| | Sodium | 2 | 2007 | 197 | 0.030 |
Why?
| | Reactive Oxygen Species | 1 | 2019 | 622 | 0.030 |
Why?
| | Administration, Oral | 1 | 2018 | 848 | 0.030 |
Why?
| | Cystatin C | 1 | 2015 | 66 | 0.030 |
Why?
| | El Salvador | 1 | 2015 | 6 | 0.030 |
Why?
| | Female | 6 | 2019 | 78605 | 0.030 |
Why?
| | Metformin | 1 | 2019 | 320 | 0.030 |
Why?
| | Eating | 1 | 2018 | 392 | 0.030 |
Why?
| | Models, Biological | 2 | 2015 | 1823 | 0.030 |
Why?
| | Saccharum | 1 | 2015 | 77 | 0.030 |
Why?
| | Adult | 4 | 2019 | 40627 | 0.030 |
Why?
| | Lipid Metabolism | 1 | 2018 | 529 | 0.030 |
Why?
| | Oxidation-Reduction | 1 | 2018 | 1087 | 0.030 |
Why?
| | Child | 3 | 2019 | 22712 | 0.030 |
Why?
| | Intestinal Mucosa | 1 | 2018 | 677 | 0.020 |
Why?
| | Up-Regulation | 1 | 2015 | 853 | 0.020 |
Why?
| | Insulin | 3 | 2008 | 2507 | 0.020 |
Why?
| | Mice, Inbred C57BL | 3 | 2009 | 6009 | 0.020 |
Why?
| | Pilot Projects | 1 | 2018 | 1894 | 0.020 |
Why?
| | Phenotype | 1 | 2019 | 3173 | 0.020 |
Why?
| | Glucose Transporter Type 5 | 1 | 2010 | 4 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2015 | 2118 | 0.020 |
Why?
| | Glucose Transporter Type 2 | 1 | 2010 | 16 | 0.020 |
Why?
| | Gastrointestinal Microbiome | 1 | 2018 | 772 | 0.020 |
Why?
| | Mice, Knockout | 2 | 2008 | 3129 | 0.020 |
Why?
| | Body Fat Distribution | 1 | 2009 | 45 | 0.020 |
Why?
| | Hyperplasia | 1 | 2010 | 177 | 0.020 |
Why?
| | Nephritis | 1 | 2009 | 22 | 0.020 |
Why?
| | Suppressor of Cytokine Signaling 3 Protein | 1 | 2008 | 11 | 0.020 |
Why?
| | Suppressor of Cytokine Signaling Proteins | 1 | 2008 | 20 | 0.020 |
Why?
| | Starvation | 1 | 2008 | 23 | 0.020 |
Why?
| | Disease Progression | 2 | 2007 | 2855 | 0.020 |
Why?
| | Time Factors | 2 | 2010 | 7186 | 0.020 |
Why?
| | Blood Glucose | 1 | 2018 | 2333 | 0.020 |
Why?
| | Age Factors | 1 | 2015 | 3339 | 0.020 |
Why?
| | Gout | 1 | 2008 | 35 | 0.020 |
Why?
| | Adenoviridae | 1 | 2008 | 199 | 0.020 |
Why?
| | Potassium, Dietary | 1 | 2007 | 12 | 0.020 |
Why?
| | Aldosterone | 1 | 2007 | 43 | 0.020 |
Why?
| | Hypertrophy | 1 | 2008 | 127 | 0.020 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2008 | 204 | 0.020 |
Why?
| | Hypothalamus | 1 | 2008 | 160 | 0.020 |
Why?
| | Actins | 1 | 2010 | 425 | 0.020 |
Why?
| | Urine | 1 | 2007 | 62 | 0.020 |
Why?
| | Hypertriglyceridemia | 1 | 2007 | 44 | 0.020 |
Why?
| | Collagen | 1 | 2010 | 456 | 0.020 |
Why?
| | Magnesium | 1 | 2007 | 155 | 0.020 |
Why?
| | Green Fluorescent Proteins | 1 | 2008 | 405 | 0.020 |
Why?
| | Triglycerides | 1 | 2009 | 521 | 0.020 |
Why?
| | Ascorbic Acid | 1 | 2008 | 180 | 0.020 |
Why?
| | Atrophy | 1 | 2007 | 201 | 0.020 |
Why?
| | Cardiovascular Diseases | 1 | 2019 | 2182 | 0.020 |
Why?
| | Fasting | 1 | 2008 | 277 | 0.020 |
Why?
| | Kidney Cortex | 1 | 2006 | 27 | 0.020 |
Why?
| | Random Allocation | 1 | 2007 | 363 | 0.020 |
Why?
| | Sodium Chloride, Dietary | 1 | 2006 | 31 | 0.020 |
Why?
| | Neovascularization, Physiologic | 1 | 2008 | 194 | 0.020 |
Why?
| | Energy Intake | 1 | 2009 | 508 | 0.010 |
Why?
| | Arterioles | 1 | 2006 | 56 | 0.010 |
Why?
| | Angiotensin II | 1 | 2006 | 97 | 0.010 |
Why?
| | Mice | 3 | 2009 | 18397 | 0.010 |
Why?
| | Vasoconstrictor Agents | 1 | 2006 | 144 | 0.010 |
Why?
| | Adenosine Triphosphate | 1 | 2008 | 505 | 0.010 |
Why?
| | Kidney Function Tests | 1 | 2005 | 157 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 2008 | 1054 | 0.010 |
Why?
| | Biopsy, Needle | 1 | 2005 | 183 | 0.010 |
Why?
| | NADPH Oxidases | 1 | 2005 | 124 | 0.010 |
Why?
| | Middle Aged | 2 | 2018 | 36021 | 0.010 |
Why?
| | Antioxidants | 1 | 2008 | 549 | 0.010 |
Why?
| | CD4 Lymphocyte Count | 1 | 2005 | 278 | 0.010 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2009 | 1217 | 0.010 |
Why?
| | NF-kappa B | 1 | 2008 | 662 | 0.010 |
Why?
| | Body Composition | 1 | 2008 | 708 | 0.010 |
Why?
| | Evolution, Molecular | 1 | 2008 | 517 | 0.010 |
Why?
| | Vasodilation | 1 | 2007 | 523 | 0.010 |
Why?
| | Fibroblasts | 1 | 2010 | 1036 | 0.010 |
Why?
| | Reference Values | 1 | 2005 | 798 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2015 | 5883 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2019 | 11731 | 0.010 |
Why?
| | Hyperglycemia | 1 | 2007 | 376 | 0.010 |
Why?
| | Cell Line | 1 | 2009 | 2882 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2005 | 1048 | 0.010 |
Why?
| | Cattle | 1 | 2005 | 1001 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2010 | 2926 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2005 | 1992 | 0.010 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2005 | 1130 | 0.010 |
Why?
| | RNA | 1 | 2005 | 940 | 0.010 |
Why?
| | Aged | 1 | 2018 | 26001 | 0.010 |
Why?
| | Cytokines | 1 | 2005 | 2066 | 0.010 |
Why?
| | Muscle, Skeletal | 1 | 2007 | 1800 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2005 | 2609 | 0.010 |
Why?
|
|
Roncal's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|